- All
- 2024
- 2023
- 2022
- 2021
- 2020
- 2019
- 2018
- 2017
- 2016
- 2015
![AmoyDx Collaborates with AstraZeneca to Co-develop HRD Companion Diagnostics for Ovarian Cancer](/upfiles/news/202102/1613721268011.png)
AmoyDx Collaborates with AstraZeneca to Co-develop HRD Companion Diagnostics for Ovarian Cancer
Xiamen, China, 19th February, 2021 – Recently Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with AstraZeneca to develop a Homologous Recombination Deficiency (HRD) Companion Diagnostic (CDx) in ovarian cancer.
![AmoyDx Collaborates with Merck KGaA, Darmstadt, Germany to Develop Companion Diagnostics for China Market](/upfiles/news/202012/1608697807046.png)
AmoyDx Collaborates with Merck KGaA, Darmstadt, Germany to Develop Companion Diagnostics for China Market
Xiamen, China, December 23, 2020 (12:30 pm) – Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Merck KGaA, Darmstadt, Germany, to develop a Companion Diagnostic (CDx) test supporting the novel MET inhibitor tepo
![AmoyDx Signs Memorandum with AstraZeneca to Cooperate in Molecular Diagnostics in Gynecological Oncology worldwide](/upfiles/news/202011/1605490007906.jpg)
AmoyDx Signs Memorandum with AstraZeneca to Cooperate in Molecular Diagnostics in Gynecological Oncology worldwide
Xiamen, China, 16th November, 2020 – Recently Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) signed a collaborative memorandum with AstraZeneca in the third China International Import Expo.
![AmoyDx EGFR Detection Method Won the 21st China's Top Patent Award](/upfiles/news/202009/1599198506423.jpg)
AmoyDx EGFR Detection Method Won the 21st China's Top Patent Award
The EGFR mutation detection method from AmoyDx (Application No.: ZL200910111499.2, Publication No.: CN101608240B) won the Silver Award of the 21st China Patent Award as recently announced by the China National Intellectual Property Administration (CNIPA).
![AmoyDx Collaborates with Haihe Pharmaceutical to Codevelop Companion Diagnostics for Japan Market](/upfiles/news/202008/1598498279783.png)
AmoyDx Collaborates with Haihe Pharmaceutical to Codevelop Companion Diagnostics for Japan Market
Xiamen, China, August 27, 2020– Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Haihe Pharmaceutical to develop a Companion Diagnostic (CDx) test supporting the novel MET inhibitor Glumetinib (SCC244). The CDx
![AmoyDx Collaborates with Merck KGaA, Darmstadt, Germany to Develop Companion Diagnostics for Japan Market](/upfiles/news/202008/1597023235387.png)
AmoyDx Collaborates with Merck KGaA, Darmstadt, Germany to Develop Companion Diagnostics for Japan Market
Xiamen, China, 9:00am, August 10, 2020– Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Merck KGaA, Darmstadt, Germany, to develop a Companion Diagnostic (CDx) test supporting the novel MET inhibitor tepotinib.
![AmoyDx Signs Agreement with AstraZeneca to Cooperate in Cancer Diagnosis in China](/upfiles/news/202007/1594187097759.png)
AmoyDx Signs Agreement with AstraZeneca to Cooperate in Cancer Diagnosis in China
Xiamen, China, 8 July, 2020– Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that recently it signed an agreement with AstraZeneca to work together closely for the molecular diagnosis of patients with cancer.
![AmoyDx Collaborates with Amgen to Develop Companion Diagnostics for China Market](/upfiles/news/202005/1590222021276.png)
AmoyDx Collaborates with Amgen to Develop Companion Diagnostics for China Market
Xiamen, China, 22 May, 2020– Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Amgen Inc. to develop Companion Diagnostic (CDx) tests supporting an investigational molecule within Amgen’s oncology portfolio. The
![AmoyDx Announces Research Collaboration with Janssen to Develop Companion Diagnostics for China Market](/upfiles/news/202003/1585055360096.jpg)
AmoyDx Announces Research Collaboration with Janssen to Develop Companion Diagnostics for China Market
Xiamen, China, 24 March, 2020–Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Janssen (China) Research & Development Center, a Division of Johnson & Johnson (China) Investment Ltd., to develop an oncology compa
![Latest News: Amoy Diagnostics born another clinical detecting center](/upfiles/news/202003/1584151239194.png)
Latest News: Amoy Diagnostics born another clinical detecting center
Shanghai Xiawei Biotechnology Co. Laboratory (hereinafter referred to as "Shanghai Xiawei") under Amoy Diagnostics passed the examination of Shanghai Municipal Health Commission and was granted the "Practice License for Medical Institutions".
![AmoyDx won the Second Prize of National Scientific and Technological Progress Award and National Enterprise Technology Center](/upfiles/news/202001/1579495422646.png)
AmoyDx won the Second Prize of National Scientific and Technological Progress Award and National Enterprise Technology Center
AmoyDx won the Second Prize of National Scientific and Technological Progress Award; AmoyDx Technology Center is qualified as "National Enterprise Technology Center".
![AmoyDx and Eisai Enter Global Diagnostic Partnership Agreement](/upfiles/news/201912/1576632657200.jpg)
AmoyDx and Eisai Enter Global Diagnostic Partnership Agreement
Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE:300685), a leading company in companion diagnostics for precision oncology, today announced that recently it signed a diagnostic partnership agreement with Eisai Co., Ltd., one of leading pharmaceutical companies i
![AmoyDx HANDLE Classic NGS Panel (HANDLE-LCP30) was recommended by ESMO as one of the NGS solutions capable of NTRK-fusion detection](/upfiles/news/201912/1576632313462.png)
AmoyDx HANDLE Classic NGS Panel (HANDLE-LCP30) was recommended by ESMO as one of the NGS solutions capable of NTRK-fusion detection
Recently, the European Society for Medical Oncology (ESMO) Translational Research and Precision Medicine Working Group (TR and PM WG) launched a collaborative project to review the available methods that can be used to detect NTRK1/2/3 gene fusions.
![AmoyDx Lung Cancer PCR Panel accepted into LC-SCRUM as Screening Test for Pharma Clinical Trials in Japan](/upfiles/news/201912/1576632440174.png)
AmoyDx Lung Cancer PCR Panel accepted into LC-SCRUM as Screening Test for Pharma Clinical Trials in Japan
Xiamen, China — September 30, 2019 -- Amoy Diagnostics Co., Ltd (AmoyDx, SZSE:300685), a leading company in companion diagnostics for precision oncology, today announced that the AmoyDx Lung Cancer PCR Panel has been accepted as first-line screening for p
![AmoyDx and PREMIA Jointly Announce Strategic Partnership to Establish Asia Cancer Clinical Genomic Network](/upfiles/news/201906/1561425967409.jpg)
AmoyDx and PREMIA Jointly Announce Strategic Partnership to Establish Asia Cancer Clinical Genomic Network
Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company, has entered into a strategic partnership agreement with Amoy Diagnostics Co., Ltd. and with PREMIA Holdings (HK) Ltd.
![Breaking News! ROS1, EGFR included on health insurance list of SK, TW](/upfiles/news/201906/1561388515537.png)
Breaking News! ROS1, EGFR included on health insurance list of SK, TW
Breaking News! South Korea Includes AmoyDx® ROS1 Kit on National Health Insurance List Taiwan, China Includes AmoyDx® EGFR Kit on Health Insurance List
![AmoyDx® BRCA1 and BRCA2 Gene Mutation Detection Kit approved by Chinese Authority](/upfiles/news/201903/1551411923205.jpg)
AmoyDx® BRCA1 and BRCA2 Gene Mutation Detection Kit approved by Chinese Authority
AmoyDx® BRCA1 and BRCA2 Gene Mutation Detection Kit was approved by Chinese National Medical Products Administration (NMPA) on February 27, 2019, intended for qualitative detection of gene BRCA1 and BRCA2 mutation in patients with different cancer types
![Sanomics Limited and Amoy Diagnostics Partner to Deliver Multi-Gene Tests in Hong Kong and Macau](/upfiles/news/201901/1548730121489.jpg)
Sanomics Limited and Amoy Diagnostics Partner to Deliver Multi-Gene Tests in Hong Kong and Macau
Xiamen, 28 January 2019 – Amoy Diagnostics Co., LTD., a leading company focusing on molecular diagnostics for precision oncology, and Sanomics Limited, a pioneering company in providing genomics tests in